Table 1.
Characteristics of AML patients by high and low MAP4K1 expression.
| Variables | MAP4K1 expression |
P-value | |
| Low expression (N=89) | High expression(N=89) | ||
| Number(%) | 89 (50%) | 89 (50%) | |
| Male,n(%) | 53 (58.9) | 45 (50.0) | 0.13 |
| Age,median(IQR),years | 54.00 (34.50, 61.00) | 50.00 (42.00, 59.00) | 0.678 |
| BM blast, median(IQR),%1 | 66.00 (43.75, 82.00) | 69.00 (49.00, 84.00) | 0.433 |
| WBC, median(IQR),ⅹ109/L2 | 18.40 (5.15, 70.15) | 13.70 (3.85, 100.75) | 0.271 |
| HB, median(IQR),g/L3 | 80.00 (66.00, 100.00) | 78.00 (64.10, 100.00) | 0.106 |
| PLT,median(IQR),ⅹ109/L4 | 45.00 (23.50, 78.00) | 42.00 (21.00, 94.50) | 0.694 |
| FAB classification,n(%)5 | 0.996 | ||
| M0 | 5 (5.6) | 2 (2.2) | |
| M1 | 3 (3.4) | 3 (3.4) | |
| M2 | 73 (80.9) | 75 (84.3) | |
| M3 | 4 (4.5) | 4 (4.5) | |
| M4 | 0 (0.0) | 0 (0.0) | |
| M5 | 0 (0.0) | 0 (0.0) | |
| M6 | 0 (0.0) | 0 (0.0) | |
| Karyotype risk, n (%) | 0.834 | ||
| Favorable | 3 (3.4) | 3 (3.4) | |
| Intermediate | 77 (86.5) | 78 (87.6) | |
| Unfavorable | 9 (10.1) | 8 (9) | |
| Genes mutations,n(%) | |||
| FLT3ITD | 17 (19.1) | 19 (21.3) | 0.704 |
| CEBPA | 24 (73.0) | 21 (23.6) | 0.790 |
| NPM1 | 27 (30.3) | 23 (25.8) | 0.395 |
| DNMT3A | 6 (6.7) | 13 (14.6) | 0.068 |
| IDH1 | 5 (5.6) | 12 (13.5) | 0.074 |
| IDH2 | 8 (9.0) | 10 (11.2) | 0.602 |
| MAP4K1,median(IQR) | 0.31 (0.23, 0.37) | 0.71 (0.54, 1.03) | 0.037 |
| Treatment protocols6 | 0.335 | ||
| DA | 18 (20.3) | 15 (16.9) | |
| IA | 46 (51.7) | 43 (48.3) | |
| HAA | 25 (28) | 31 (34.8) | |
Abbreviations:1BM, bone marrow; 2WBC, white blood cell; 3HB, hemoglobin; 4PLT, platelet counts; 5FAB, French–American–British classification systems. 6 The protocols used for induction therapy in different groups including donorubicin/Ara-C (DA)-based treatment group, idarubicin/Ara-C (IA)-based, and homoharringtonine/Ara-C/aclarubicin (HAA)-based treatment group.